These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 27534434)

  • 1. Antipsychotic drugs in Huntington's disease.
    Unti E; Mazzucchi S; Palermo G; Bonuccelli U; Ceravolo R
    Expert Rev Neurother; 2017 Mar; 17(3):227-237. PubMed ID: 27534434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment options for chorea.
    Bashir H; Jankovic J
    Expert Rev Neurother; 2018 Jan; 18(1):51-63. PubMed ID: 29120264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current Pharmacological Approaches to Reduce Chorea in Huntington's Disease.
    Coppen EM; Roos RA
    Drugs; 2017 Jan; 77(1):29-46. PubMed ID: 27988871
    [TBL] [Abstract][Full Text] [Related]  

  • 4. State-of-the-art pharmacological approaches to reduce chorea in Huntington's disease.
    Gibson JS; Claassen DO
    Expert Opin Pharmacother; 2021 Jun; 22(8):1015-1024. PubMed ID: 33550875
    [No Abstract]   [Full Text] [Related]  

  • 5. Deutetrabenazine for the treatment of Huntington's chorea.
    Bashir H; Jankovic J
    Expert Rev Neurother; 2018 Aug; 18(8):625-631. PubMed ID: 29996061
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advances in the pharmacological management of Huntington's disease.
    Frank S; Jankovic J
    Drugs; 2010 Mar; 70(5):561-71. PubMed ID: 20329804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pridopidine for the treatment of Huntington's disease.
    Shannon KM
    Expert Opin Investig Drugs; 2016; 25(4):485-92. PubMed ID: 26881734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A systematic review of the treatment studies in Huntington's disease since 1990.
    Bonelli RM; Hofmann P
    Expert Opin Pharmacother; 2007 Feb; 8(2):141-53. PubMed ID: 17257085
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An evidence-based approach in the treatment of Huntington's disease.
    Mestre TA; Ferreira JJ
    Parkinsonism Relat Disord; 2012 May; 18(4):316-20. PubMed ID: 22177624
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Guidelines for clinical pharmacological practices in Huntington's disease.
    Désaméricq G; Youssov K; Charles P; Saleh N; Olivier A; Sherer-Gagou C; Verny C; ; Bachoud-Lévi AC
    Rev Neurol (Paris); 2016; 172(8-9):423-432. PubMed ID: 27561440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary.
    Kane JM; Leucht S; Carpenter D; Docherty JP;
    J Clin Psychiatry; 2003; 64 Suppl 12():5-19. PubMed ID: 14640142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current therapeutic options for Huntington's disease: good clinical practice versus evidence-based approaches?
    Killoran A; Biglan KM
    Mov Disord; 2014 Sep; 29(11):1404-13. PubMed ID: 25164707
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dopamine depleters in the treatment of hyperkinetic movement disorders.
    Jankovic J
    Expert Opin Pharmacother; 2016 Dec; 17(18):2461-2470. PubMed ID: 27819145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological management of Huntington's disease: an evidence-based review.
    Bonelli RM; Wenning GK
    Curr Pharm Des; 2006; 12(21):2701-20. PubMed ID: 16842168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of Huntington's disease.
    Frank S
    Neurotherapeutics; 2014 Jan; 11(1):153-60. PubMed ID: 24366610
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Prevention and treatment of tardive dyskinesia caused by antipsychotic drugs].
    Seigneurie AS; Sauvanaud F; Limosin F
    Encephale; 2016 Jun; 42(3):248-54. PubMed ID: 26922134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An experimental model for Huntington's chorea?
    Zeef DH; Jahanshahi A; Vlamings R; Casaca-Carreira J; Santegoeds RG; Janssen ML; Oosterloo M; Temel Y
    Behav Brain Res; 2014 Apr; 262():31-4. PubMed ID: 24412685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of chorea associated with Huntington's disease: focus on tetrabenazine.
    Setter SM; Neumiller JJ; Dobbins EK; Wood L; Clark J; DuVall CA; Santiago A
    Consult Pharm; 2009 Jul; 24(7):524-37. PubMed ID: 19689181
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuroleptic malignant syndrome related to tetrabenazine introduction and haloperidol discontinuation in Huntington's disease.
    Mateo D; Muñoz-Blanco JL; Giménez-Roldán S
    Clin Neuropharmacol; 1992 Feb; 15(1):63-8. PubMed ID: 1533561
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A review of the treatment options for Huntington's disease.
    Bonelli RM; Hofmann P
    Expert Opin Pharmacother; 2004 Apr; 5(4):767-76. PubMed ID: 15102562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.